- Investing Ideas
- Swiss Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Swiss Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
2
0 new
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
2 companies
Idorsia
Market Cap: CHF 1.7b
A biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada.
IDIA
CHF 6.86
7D
20.9%
1Y
239.6%
Galderma Group
Market Cap: CHF 41.8b
Operates as a dermatology company worldwide.
GALD
CHF 178.25
7D
3.4%
1Y
50.4%